- Zacks
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
- Motley Fool
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
One key issue remains unresolved, and it could be a significant one.
- Motley Fool
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.
